secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xencor Inc (XNCR)
CIK:        0001326732
Form:       8-K
Filed at:   2026-08-05T20:01:16+00:00
Accession:  0001326732-26-000055
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xencor Q2 net loss $21.7M; Alexion settlement $105M; XmAb819 ESMO presentation
------------------------------------------------------------------------------

- Q2 2026 revenue $51.2M (up from $43.6M YoY); net loss $21.7M ($0.29 loss per share) vs $30.8M loss in Q2 2025.
- Alexion settlement resolves Ultomiris royalty dispute: $105M total, first $52.5M due Aug 2026, second $52.5M in 2027; no further U.S. royalties.
- XmAb819 (ENPP3 x CD3) Phase 1 ccRCC data accepted for oral presentation at ESMO 2026; registration-enabling study planned for 2027.
- XmAb541 (CLDN6 x CD3) monotherapy shows ~14% ORR in ovarian, ~28% in germ cell tumors; FDA Fast Track for germ cell; combination with XmAb808 prioritized.
- Cash $486.4M at June 30, 2026; expects year-end 2026 cash $420-440M; sufficient to fund operations through 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326732/000132673226000055/0001326732-26-000055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326732/000132673226000055/xncr-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001326732-26-000055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer